BCL2L1 and hepatocellular carcinoma: A combinatorial effect of ABT-263, an inhibitor of Bcl-2, Bcl-XL, and Bcl-w, together with anti-angiogenic TKI’s was already reported in HepG2 liver carcinoma cell lines in vitro.